AstraZeneca’s COVID-19 vaccine manufactured in Thailand authorised for World Health Organization Emergency Use

AstraZeneca’s COVID-19 vaccine manufactured in Thailand has been authorised under the World Health Organization (WHO) Emergency Use Listing (EUL) procedure, with immediate effect.

In February 2021, the WHO granted EUL to AstraZeneca’s COVID-19 vaccine, enabling global access during the pandemic. This EUL authorisation has been extended to now include doses manufactured by Siam Bioscience, AstraZeneca’s production partner in Thailand, and recognises that COVID-19 Vaccine AstraZeneca or Vaxzevria is the same product wherever it is made.

Dr Sanjeev Panchal, Country President, AstraZeneca Malaysia, said: “The World Health Organization’s emergency listing of our vaccine is good news for people in Malaysia and worldwide. It will provide more assurance for governments to recognise the vaccine and allow people to travel again, reconnecting families, opening up economies, and supporting a return to normality.”

Nualphan Lamsam, Honorary Director of Corporate Communications, Siam Bioscience Co., Ltd., said: “Siam Bioscience is proud to have been selected by AstraZeneca as its local manufacturing partner. We take great pride in producing high-quality COVID-19 vaccine, now recognised by the World Health Organization. All batches of AstraZeneca’s COVID-19 vaccine produced at Siam Bioscience, undergo stringent quality testing and are also authorised by regulators and international laboratories in Europe and the U.S. Siam Bioscience and AstraZeneca continue to work closely and produce vaccine doses for the wellbeing of the Thai people and region, to help a quick return to normalcy.”

All manufacturing of COVID-19 Vaccine AstraZeneca around the world is conducted using the same stringent manufacturing process and each batch passes over 60 quality tests as part of a robust global quality assurance process.

To date, more than 1.5 billion doses of AstraZeneca’s vaccine have been released for supply to more than 170 countries globally, and approximately two-thirds of these doses have been delivered to low- and lower-middle income countries.

 

COVID-19 Vaccine AstraZeneca

The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

For more information about COVID-19 Vaccine AstraZeneca, please visit https://www.azcovid-19.com/asia/th/th.html.

Contact

For further details please contact Pucharapan Holim, Communications Manager, pucharapan.holim@astrazeneca.com, +66 (0) 86 999 8587.